Investigation of Laboratory and Clinical Feature in the Patients with Myeloproliferative Neoplasm Co-expression of BCR-ABL1 and JAK2 V617F.
10.19746/j.cnki.issn.1009-2137.2021.04.033
- Author:
Xiao-Geng YUAN
1
;
Run-Tao WAN
2
;
Xiao-Wu ZHAO
3
;
Xiao-Zhe YANG
4
;
Jin XIAO
4
Author Information
1. Department of Hematology, Henan Xinhe Hospital, Xinyang 465000, Henan Province, China,Key Laboratory of Hematology, Zhengzhou Jinyu Clinical Laboratory Center, Zhengzhou 450016, Henan Province, China.
2. Department of Hematology, Henan Xinhe Hospital, Xinyang 465000, Henan Province, China.
3. Key Laboratory of Hematology, Zhengzhou Jinyu Clinical Laboratory Center, Zhengzhou 450016, Henan Province, China,E-mail: zz-zhaoxiaowu@kingmed.com.cn.
4. Department of Hematology, Puyang People's Hospital, Puyang 457000, Henan Province, China.
- Publication Type:Journal Article
- MeSH:
Aged;
Fusion Proteins, bcr-abl/genetics*;
Humans;
Janus Kinase 2/genetics*;
Laboratories;
Mutation;
Myeloproliferative Disorders/genetics*;
Polycythemia Vera
- From:
Journal of Experimental Hematology
2021;29(4):1236-1241
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the comprehensive laboratory test data of BCR-ABL1 fusion gene and JAK2 V617F mutation co-expressed in myeloproliferative neoplasm (MPN) patients, and investigate its relative clinical significance.
METHODS:Data of 1 332 MPN patients were comprehensively analyzed, BCR-ABL1 (P190/P210/P230) fusion gene and JAK2 V617F mutation were detected by real time-polymerase chain reaction (RT-PCR) technique, the CALR, MPL, JAK2 12 and 13 exon mutations were detected by the First Generation Sequencing, the bone marrow cell morphology and pathological characteristics were evaluated by bone marrow smear and biopsy technique, the immune phenotypes of bone marrow cells were evaluated by flow cytometry, the chromosome karyotypes of bone marrow cells were analyzed by chromosome G banding technique.
RESULTS:Four of the 1 332 patients were found to have the co-existence of BCR-ABL1 fusion gene and the JAK2 V617F mutation, with a 0.3% incidence and a median age of 70 years old, including 2 cases of polycythemia vera, 1 case of primary myelofibrosis, and 1 case of chronic myeloid leukemia-accelerated phase. The clues of double positive genes of such patients at the time of initial diagnose could not be cued only by age, physical signs and cell morphology, they should be analyzed by comprehensive test data.
CONCLUSION:The co-existence of BCR-ABL1 fusion gene and JAK2 V617F mutation in the same case is a kind of disease with special clinical significance. The application of multiple detection methods can improve the detection of this disease, which is conducive to early detection, reasonable diagnosis and treatment by clinicians.
